Cargando…

PI3K Inhibition Enhances Doxorubicin-Induced Apoptosis in Sarcoma Cells

We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis. PI103 decreased the expression of MDR1 and MRP1, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marklein, Diana, Graab, Ulrike, Naumann, Ivonne, Yan, Tiandong, Ridzewski, Rosalie, Nitzki, Frauke, Rosenberger, Albert, Dittmann, Kai, Wienands, Jürgen, Wojnowski, Leszek, Fulda, Simone, Hahn, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534123/ https://www.ncbi.nlm.nih.gov/pubmed/23300809 http://dx.doi.org/10.1371/journal.pone.0052898

Ejemplares similares

Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma
por: Graab, Ulrike, et al.
Publicado: (2015)

Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors
por: Geyer, Natalie, et al.
Publicado: (2018)

Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell Lines
por: Ridzewski, Rosalie, et al.
Publicado: (2015)

Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death
por: Schott, Christina, et al.
Publicado: (2015)

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
por: Deng, Shiwei, et al.
Publicado: (2014)

Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice
por: Deng, Shiwei, et al.
Publicado: (2009)

Patched Knockout Mouse Models of Basal Cell Carcinoma
por: Nitzki, Frauke, et al.
Publicado: (2012)

Depletion of Cutaneous Macrophages and Dendritic Cells Promotes Growth of Basal Cell Carcinoma in Mice
por: König, Simone, et al.
Publicado: (2014)

Overexpression of mutant Ptch in rhabdomyosarcomas is associated with promoter hypomethylation and increased Gli1 and H3K4me3 occupancy
por: Nitzki, Frauke, et al.
Publicado: (2015)

Regulation and Role of GLI1 in Cutaneous Squamous Cell Carcinoma Pathogenesis
por: Pyczek, Joanna, et al.
Publicado: (2019)

Sarcoma of the Mediastinum of a Rhinoceros
por: Rosenberger, Randle C.
Publicado: (1901)

Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy
por: Merimsky, Ofer, et al.
Publicado: (2000)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
por: Liffers, Sven-T, et al.
Publicado: (2013)

Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
por: Narayan, Hari K, et al.
Publicado: (2019)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms
por: Bauer, Julia, et al.
Publicado: (2021)

PP2A-B56 opposes Mps1 phosphorylation of Knl1 and thereby promotes spindle assembly checkpoint silencing
por: Espert, Antonio, et al.
Publicado: (2014)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022)

Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin
por: Li, Jieli, et al.
Publicado: (2020)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients
por: URAKAWA, HIROSHI, et al.
Publicado: (2014)

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin
por: Borlle, Lucia, et al.
Publicado: (2019)

Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
por: Torrigiani, Filippo, et al.
Publicado: (2019)

Doxorubicin and ifosfamide for recurrent renal synovial sarcoma: The first case report in Indonesia
por: Fitra, Ahmad Fathira, et al.
Publicado: (2022)

Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models
por: Gallego, Borja, et al.
Publicado: (2022)

Reactivation of IgG-switched memory B cells by BCR-intrinsic signal amplification promotes IgG antibody production
por: Lutz, Johannes, et al.
Publicado: (2015)

IgG antibody titers to SARS-CoV-2 reveal a distinct efficacy of multiple sclerosis-modifying therapies to curtail lymphocyte compartments
por: Wienands, Jürgen
Publicado: (2021)

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin
por: Tang, H-J, et al.
Publicado: (2004)

Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females
por: Zanetta, G, et al.
Publicado: (1999)

A Case of Renal Synovial Sarcoma: Complete Remission was Induced by Chemotherapy with Doxorubicin and Ifosfamide.
por: Park, Soo-Jin, et al.
Publicado: (2004)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report
por: Mirza, Yasir Azim, et al.
Publicado: (2015)

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
por: Gong, Jun, et al.
Publicado: (2018)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ssr8os3b0dfg9qcf5qkphopssj